Guildford’s Futura Medical extends collaboration with Cooper Consumer Health
Guildford pharmaceutical firm Futura Medical has extended its exclusive licensing agreement with Cooper Consumer Health up to January 2029.
Futura Medical, which develops sexual health products, will retain rights to commercialise Cooper’s topical, gel-based erectile dysfunction treatment Eroxon throughout the UK and Europe.
The product has become the first pan-European topical treatment for ED available without prescription.
Initial launches in the UK and Belgium last March will be followed by further expansion into Italy, Spain, France and Germany this year.
Visit Hampshire Biz News for bright, upbeat and positive business news from the county
James Barder, CEO of Futura Medical said: “The award-winning launch of Eroxon was a key milestone in our partnership with Cooper and the success of our collaboration makes this extension an easy decision for both parties.
“We’re committed to providing treatment to those suffering from ED and as such we continue the commercial rollout of Eroxon across the world.”
This latest extension builds upon the initial five-year agreement signed in May 2022. Futura will continue to supply Eroxon through its third-party contract manufacturers.
Bart Meermans, president of Cooper Consumer Health, added: “Cooper’s ambition is to become a leading European consumer healthcare platform.
“Eroxon is an exciting new innovation for the erectile dysfunction market and we look forward to working closely with Futura with the continuing launches of Eroxon across our markets.”
Read more - Guildford's Eagle Eye launches AI designed for retail
